Entrectinib latest price trends and purchasing suggestions

Entrectinib is a multi-target oral tyrosine kinase inhibitor, mainly used to treat ROS1-positive non-small cell lung cancer (NSCLC) and NTRK fusion gene-positive solid tumors. As an important drug in the field of precision therapy, entrectinib has attracted widespread attention since it was approved for marketing in China in 2022. It is highly targeted and has relatively few side effects. It is especially suitable for some patients with advanced tumors carrying specific gene mutations, filling the gap in treatment options for ROS1 and NTRK-positive patients.

Currently, entrectinib has been included in China's national medical insurance directory and is suitable for patients with ROS1positive advanced NSCLC and NTRK fusion solid tumors. After being included in medical insurance, the price of the drug has dropped significantly, and the actual burden on patients has been significantly reduced after reimbursement. Taking the 200mg specification as an example, the price per box is about 2 to 2.7yuan. The reimbursement ratio of medical insurance varies according to regional differences. In most cities, the out-of-pocket portion is between 5,000 and 10,000 yuan. The implementation of medical insurance policies has made such high-priced targeted drugs more accessible, bringing practical economic burden relief to patients.

In addition to original drugs, there are also many overseas generic versions on the market, especially those produced in Laos at the most affordable prices. The common specifications of the Lao version of entrectinib are 100mg*60 tablets. The price per box is about RMB 1,000 to RMB 2,000, and the ingredients are basically the same as the original drug. For patients who are not eligible for medical insurance reimbursement or are under great financial pressure, generic drugs have become a viable alternative. However, when purchasing, be sure to go through formal channels to avoid buying fake or inferior products.

Generally speaking, the price of entrectinib in the domestic market has been reduced due to the medical insurance policy. The original drug has higher medication protection, while the Lao generic drug provides a price advantage. When selecting drugs, patients should comprehensively consider efficacy, economic conditions and doctor's advice to ensure the best treatment effect within an affordable range. Regardless of whether you choose original research or generic drugs, you should follow standardized medication routes to ensure the safety and effectiveness of treatment.

Reference: https://go.drugbank.com/drugs/